Coherus Biosciences (NASDAQ:CHRS) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a hold rating to a buy rating in a report published on Monday, February 4th.

A number of other research firms have also recently commented on CHRS. Zacks Investment Research upgraded Coherus Biosciences from a hold rating to a buy rating and set a $13.00 price objective for the company in a research report on Tuesday, October 30th. BidaskClub cut Coherus Biosciences from a sell rating to a strong sell rating in a research report on Tuesday, October 9th. Cowen restated a buy rating and issued a $45.00 price objective on shares of Coherus Biosciences in a research report on Friday, November 2nd. Finally, HC Wainwright set a $28.00 price objective on Coherus Biosciences and gave the company a buy rating in a research report on Monday, November 5th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $27.20.

CHRS stock traded up $0.02 during trading on Monday, hitting $14.36. 1,232,815 shares of the company traded hands, compared to its average volume of 704,263. The stock has a market cap of $976.91 million, a P/E ratio of -4.46 and a beta of 3.66. Coherus Biosciences has a 1 year low of $8.32 and a 1 year high of $20.66. The company has a current ratio of 5.31, a quick ratio of 5.31 and a debt-to-equity ratio of 8.29.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CHRS. Legal & General Group Plc lifted its stake in shares of Coherus Biosciences by 12.3% in the 4th quarter. Legal & General Group Plc now owns 9,095 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 998 shares during the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of Coherus Biosciences in the 2nd quarter valued at $118,000. Roman Butler Fullerton & Co. acquired a new position in shares of Coherus Biosciences in the 4th quarter valued at $122,000. State Board of Administration of Florida Retirement System lifted its stake in shares of Coherus Biosciences by 16.5% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 22,095 shares of the biotechnology company’s stock valued at $200,000 after purchasing an additional 3,122 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Coherus Biosciences in the 3rd quarter valued at $282,000. 96.74% of the stock is currently owned by institutional investors.

About Coherus Biosciences

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Read More: What is a Reverse Stock Split?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply